2Mon·

Bavarian Nordic and BioNTech are two interesting companies in the field of Mpox vaccines. Bavarian Nordic offers the only licensed vaccine (MVA-BN) and is expanding globally to meet the growing demand. BioNTech, on the other hand, is developing an mRNA vaccine that could ensure flexible and rapid production thanks to its technology. $BAVA (-1.93%)
$BNTX (-2.25%)

Bavarian Nordic has proven products, while BioNTech could convince through innovation. Both companies offer a lot of potential, but which approach is more successful in the long term? What do you think?

6
8 Comments

profile image
Biontech is a long play for me. For many, it's just a Covid share, but if it works with the personalized cancer vaccine, it's a game changer.

I think the monkeypox issue is more of a flash in the pan.
14
View all 7 further answers
Join the conversation